Human Genome Sciences Benlysta Drug Approval HGSI FDA Panel

StockMarketFunding.com reports that Human Genome Sciences FDA Panel Recommendation for Benlysta may cause any large biotechnology players to look at HGSI as a takeover target. The main company with a vested interest in the equity is GSK GlaxoSmithKline with $10.24B billion in cash. GSK stands to split the revenues generated with HGSI's Benlysta 50/50. Analyst have said that Benlysta sales could reach between $3-5 Billion dollars by 2014.